Standard diagnostics with and without urine-based lipoarabinomannan testing for tuberculosis disease in HIV-infected patients in a high-burden setting–A cost-effectiveness analysis

Background Recent clinical findings reported the reduced mortality associated with treatment guided by sputum-based molecular test with urine-based lipoarabinomannan (LAM) assay for tuberculosis (TB) disease in HIV-infected individuals. We aimed to evaluate the cost-effectiveness of sputum-based Xpert tests with and without urine-based LAM assays among HIV-infected individuals with signs and symptoms of TB disease (TBD) from the perspective of South African healthcare providers. Methods A one-year decision-analytic model was constructed to simulate TB-related outcomes of 7 strategies: Sputum smear microscope (SSM), Xpert, Xpert Ultra, Xpert with AlereLAM, Xpert Ultra with AlereLAM, Xpert with FujiLAM, and Xpert Ultra with FujiLAM, in a hypothetical cohort of adult HIV-infected individuals with signs and symptoms of TB. The model outcomes were TB-related direct medical cost, mortality, early treatment, disability-adjusted life-years (DALYs) and incremental cost per DALY averted (ICER). The model inputs were retrieved from literature and public data. Base-case analysis and sensitivity analysis were conducted. Results In the base-case analysis, the Xpert Ultra with FujiLAM strategy showed the highest incidence of early treatment (267.7 per 1000 tested) and lowest mortality (29.0 per 1000 tested), with ICER = 676.9 USD/DALY averted. Probabilistic sensitivity analysis of 10,000 Monte Carlo simulations showed the cost-effective probability of Xpert Ultra with FujiLAM was the highest of all 7 strategies at the willingness-to-pay (WTP) threshold >202USD/DALY averted. Conclusion Standard sputum-based TB diagnostic Xpert Ultra with urine-based FujiLAM for TBD testing in HIV-infected individuals appears to be the preferred cost-effective strategy from the perspective of the health service provider of South Africa.

[1]  P. Bester,et al.  Sedentariness and overweight in relation to mortality in sub-Saharan Africa. A mediation analysis based on the World Health Organization-Global Health Observatory data repository , 2023, Journal of public health in Africa.

[2]  Yue Zhang,et al.  Bedaquiline and Linezolid improve anti-TB treatment outcome in drug-resistant TB patients with HIV: A systematic review and meta-analysis. , 2022, Pharmacological research.

[3]  N. Menon,et al.  Point-of-care diagnostic tests for tuberculosis disease , 2022, Science Translational Medicine.

[4]  A. Mocroft,et al.  Delayed diagnosis of tuberculosis in persons living with HIV in Eastern Europe: associated factors and effect on mortality—a multicentre prospective cohort study , 2021, BMC Infectious Diseases.

[5]  K. Steingart,et al.  Impact of diagnostic strategies for tuberculosis using lateral flow urine lipoarabinomannan assay in people living with HIV , 2021, The Cochrane database of systematic reviews.

[6]  A. Welte,et al.  Mortality during tuberculosis treatment in South Africa using an 8-year analysis of the national tuberculosis treatment register , 2021, Scientific Reports.

[7]  L. Chávez-Galán,et al.  Lipoarabinomannan as a Point-of-Care Assay for Diagnosis of Tuberculosis: How Far Are We to Use It? , 2021, Frontiers in Microbiology.

[8]  N. Dendukuri,et al.  Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosis. , 2021, The Cochrane database of systematic reviews.

[9]  R. Walensky,et al.  Cost-effectiveness of a Novel Lipoarabinomannan Test for Tuberculosis in Patients With Human Immunodeficiency Virus , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  C. Denkinger,et al.  Diagnostic accuracy of a novel tuberculosis point-of-care urine lipoarabinomannan assay for people living with HIV: A meta-analysis of individual in- and outpatient data , 2020, PLoS medicine.

[11]  S. Wanjala,et al.  Cost-effectiveness of diagnostic algorithms including lateral-flow urine lipoarabinomannan for HIV-positive patients with symptoms of tuberculosis , 2020, PloS one.

[12]  C. Denkinger,et al.  Diagnostic Accuracy of a Novel and Rapid Lipoarabinomannan Test for Diagnosing Tuberculosis Among People With Human Immunodeficiency Virus , 2019, Open forum infectious diseases.

[13]  C. Denkinger,et al.  Novel lipoarabinomannan point-of-care tuberculosis test for people with HIV: a diagnostic accuracy study , 2019, The Lancet. Infectious diseases.

[14]  P. Das,et al.  Sputum smear microscopy in tuberculosis: It is still relevant in the era of molecular diagnosis when seen from the public health perspective , 2019, Biomedical and Biotechnology Research Journal (BBRJ).

[15]  R. Walensky,et al.  Cost-effectiveness of urine-based tuberculosis screening in hospitalised patients with HIV in Africa: a microsimulation modelling study. , 2019, The Lancet. Global health.

[16]  A. Garcia-Basteiro,et al.  Point of care diagnostics for tuberculosis. , 2018, Pulmonology.

[17]  G. Maartens,et al.  South African guideline for the management of community-acquired pneumonia in adults. , 2017, Journal of thoracic disease.

[18]  K. Dheda,et al.  Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trial , 2016, The Lancet.

[19]  Christopher Dye,et al.  Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIF. , 2015, The Lancet. Global health.

[20]  H. Cox,et al.  Cost per patient of treatment for rifampicin‐resistant tuberculosis in a community‐based programme in Khayelitsha, South Africa , 2015, Tropical medicine & international health : TM & IH.

[21]  M. Pai,et al.  Replacing smear microscopy for the diagnosis of tuberculosis: what is the market potential? , 2014, European Respiratory Journal.

[22]  S. Dorman,et al.  Cost-effectiveness of novel algorithms for rapid diagnosis of tuberculosis in HIV-infected individuals in Uganda , 2013, AIDS.

[23]  M. Pai,et al.  Robust, reliable and resilient: designing molecular tuberculosis tests for microscopy centers in developing countries , 2013, Expert review of molecular diagnostics.

[24]  M. Joloba,et al.  Meta-analysis to compare the accuracy of GeneXpert, MODS and the WHO 2007 algorithm for diagnosis of smear-negative pulmonary tuberculosis , 2013, BMC Infectious Diseases.

[25]  S. Dorman,et al.  Comparison of laboratory costs of rapid molecular tests and conventional diagnostics for detection of tuberculosis and drug-resistant tuberculosis in South Africa , 2013, BMC Infectious Diseases.

[26]  S. Dorman,et al.  Cost utility of lateral-flow urine lipoarabinomannan for tuberculosis diagnosis in HIV-infected African adults. , 2013, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[27]  K. Dheda,et al.  What is the Cost of Diagnosis and Management of Drug Resistant Tuberculosis in South Africa? , 2013, PloS one.

[28]  R. Baltussen,et al.  Costs and process of in-patient tuberculosis management at a central academic hospital, Cape Town, South Africa. , 2012, Public health action.

[29]  Uwe Siebert,et al.  Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--1. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[30]  S. Lawn,et al.  Tuberculosis Incidence Rates during 8 Years of Follow-Up of an Antiretroviral Treatment Cohort in South Africa: Comparison with Rates in the Community , 2012, PloS one.

[31]  S. Whitehead,et al.  Health Related Quality of Life among Patients with Tuberculosis and HIV in Thailand , 2012, PloS one.

[32]  Isao Kamae,et al.  The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[33]  Mark Sculpher,et al.  Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[34]  C. F. von Reyn,et al.  Sputum microscopy for the diagnosis of HIV-associated pulmonary tuberculosis in Tanzania , 2008, BMC public health.

[35]  Evan Wood,et al.  Population health: Concepts and methods , 2000 .

[36]  D. Fryback,et al.  Toward consistency in cost-utility analyses: using national measures to create condition-specific values. , 1998, Medical care.

[37]  C. Dolea,et al.  World Health Organization , 1949, International Organization.

[38]  Market assessment of tuberculosis diagnostics in South Africa, 2012-2013. , 2015, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[39]  J. Severens,et al.  Utilities of the EQ-5D , 2012, PharmacoEconomics.

[40]  J. Guilbert.  The world health report 2002 - reducing risks, promoting healthy life. , 2003, Education for health.

[41]  Milton C Weinstein,et al.  Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies. , 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[42]  D. Fryback,et al.  HALYS and QALYS and DALYS, Oh My: similarities and differences in summary measures of population Health. , 2002, Annual review of public health.

[43]  C. Murray,et al.  Global burden of disease , 1997, The Lancet.